Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency by Abu Bakar, Nurulamin et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring
in phosphoglucomutase-I deficiency
Abu Bakar, Nurulamin; Voermans, Nicol C; Marquardt, Thorsten; Thiel, Christian; Janssen,
Mirian C H; Hansikova, Hana; Crushell, Ellen; Sykut-Cegielska, Jolanta; Bowling, Francis;
MØrkrid, Lars; Vissing, John; Morava, Eva; van Scherpenzeel, Monique; Lefeber, Dirk J
Published in:
Translational Research
DOI:
10.1016/j.trsl.2018.04.008
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Abu Bakar, N., Voermans, N. C., Marquardt, T., Thiel, C., Janssen, M. C. H., Hansikova, H., ... Lefeber, D. J.
(2018). Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in
phosphoglucomutase-I deficiency. Translational Research, 199, 62-76. https://doi.org/10.1016/j.trsl.2018.04.008
Download date: 03. Feb. 2020
Intact transferrin and total plasma
glycoprofiling for diagnosis and therapy
monitoring in phosphoglucomutase-I
deficiencyD1X XNURULAMIN ABU BAKARD2X X, D3X XNICOL C. VOERMANSD4X X, D5X XTHORSTEN MARQUARDTD6X X, D7X XCHRISTIAN THIELD8X X,
D9X XMIRIAN C.H. JANSSEND10X X, D11X XHANA HANSIKOVAD12X X, D13X XELLEN CRUSHELLD14X X, D15X XJOLANTA SYKUT-CEGIELSKA D16X X,
D17X XFRANCIS BOWLINGD18X X, D19X XLARS MØRKRIDD20X X, D21X XJOHN VISSINGD22X X, D23X XEVA MORAVAD24X X,
D25X XMONIQUE VAN SCHERPENZEELD26X X, and D27X X IRK J. LEFEBERD28X X
NIJMEGEN, THE NETHERLANDS; MUENSTER, AND HEIDELBERG, GERMANY; PRAGUE, CZECH REPUBLIC; DUBLIN, REPUBLIC OF IRE-
LAND; WARSAW, POLAND; SOUTH BRISBANE, AUSTRALIA; NORWAY; DENMARK; AND ROCHESTER, MINNESOTAFrom the Department of Neurology
sity Medical Center, Nijmegen, The
University Hospital Muenster, Mu
Heidelberg, Germany; Department
and Adolescent Medicine, First Fac
lic; Academic Centre on Rare Dise
Paediatrics, Institute of Mother and
tralia; Institute of Clinical Biochem
tal, Norway; Department of Neuro
Minnesota; Translational Metabolic
Submitted for Publication March 28
Reprint requests: Dirk J. Lefeber, T
6500 HB Nijmegen, The Netherlan
1931-5244/$ - see front matter
 2018 The Author(s). Published
licenses/by-nc-nd/4.0/)
https://doi.org/10.1016/j.trsl.2018.0Phosphoglucomutase 1 (PGM1) deficiency results in a mixed phenotype of a Glyco-
gen Storage Disorder and a Congenital Disorder of Glycosylation (CDG). Screening for
abnormal glycosylation has identified more than 40 patients, manifesting with a broad
clinical and biochemical spectrum which complicates diagnosis. Together with the
availability of D-galactose as dietary therapy, there is an urgent need for specific gly-
comarkers for early diagnosis and treatment monitoring. We performed glycomics pro-
filing by high-resolution QTOF mass spectrometry in a series of 19 PGM1-CDG patients,
covering a broad range of biochemical and clinical severity. Bioinformatics and statis-
tical analysis were used to select glycomarkers for diagnostics and define glycan-
indexes for treatment monitoring. Using 3 transferrin glycobiomarkers, all PGM1-CDG
patients were diagnosed with 100% specificity and sensitivity. Total plasma glycoprofil-
ing showed an increase in high mannose glycans and fucosylation, while global gal-
actosylation and sialylation were severely decreased. For treatment monitoring, we
defined 3 glycan-indexes, reflecting normal glycosylation, a lack of complete glycans
(LOCGI) and of galactose residues (LOGI). These indexes showed improved glycosyla-
tion upon D-galactose treatment with a fast and near-normalization of the galactose
index (LOGI) in 6 out of 8 patients and a slower normalization of the LOCGI in all
patients. Total plasma glycoprofiling showed improvement of the global highmannose
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Volume 199 Abu Bakar et al 63Our study indicates specific glycomarkers for diagnosis of mildly and severely affected
PGM1-CDG patients, and to monitor the glycan-specific effects of D-galactose ther-
apy. (Translational Research 2018; 199:6276)Abbreviations: PGM1 = phosphoglucomutase-1; G1P = glucose-1-phosphate; CDG = congeni-
tal disorder of glycosylation; CDG-I = CDG type-1; CDG-II = CDG type-2; MS =mass spectrome-
try; TIEF = transferrin isoelectric focusing; ApoC-III = apolipoprotein C-III; IEF = isoelectric
focusing; v/v = volume/volume; PGC-chip = porous graphitized carbon chip; CI = confidence
intervals; NGI = normal glycan index; LOCGI = lack of complete glycan index; LOGI = lack of
galactose index; ER = endoplasmic reticulumAt a Glance Commentary
Abu Bakar, Nurulamin, et al.Background
Early recognition of phosphoglucomutase-I defi-
ciency (PGM1-CDG) is crucial to initiate meta-
bolic interventions. However, diagnosis of
PGM1-CDG is highly challenging due to the large
clinical and biochemical heterogeneity. We per-
fomed glycomics profiling by mass spectrometry
to identify unique glycomarkers.
Translational Significance
Specific transferrin glycoforms were identified for
fast and accurate diagnosis of the full range of
clinical presentations, and for monitoring of spe-
cific effects of oral D-galactose therapy. These
glycomarkers will result in early diagnosis of
novel PGM1-CDG patients, and allow further
optimization of oral D-galactose as supplementa-
tion therapy.INTRODUCTION
Phosphoglucomutase 1 (PGM1) deficiency was first
reported in an adult patient with exercise-induced muscle
cramps and several episodes of rhabdomyolysis, desig-
nated as glycogen storage disorder type XIV. Phospho-
glucomutase 1 is a cytosolic enzyme that interconverts
glucose-1-phosphate and glucose-6-phosphate, and is
thus essential to generate energy via the glycolytic path-
way from glucose-1-phosphate, as released from glyco-
gen upon exercise.1 In a cohort of unsolved Congenital
Disorders of Glycosylation (CDG) patients, PGM1 muta-
tions (PGM1-CDG) were found in 2 children with multi-
system features, including cleft palate, short stature,
cardiomyopathy, hypoglycemia, liver function and endo-
crine abnormalities, and hypoglycemia.2
Genetic analysis of additional cohorts of unsolved CDG
patients revealed a large group of 19 PGM1-CDG patients,
with mixed CDG-type 1 (CDG-I) and CDG-type 2 (CDG-
II) screening profiles. The clinical presentation rangedfrom a predominant liver involvement, early-onset hypo-
glycaemia to myopathy with or without the multisystem
features as described above. Mass spectrometry (MS) of
intact transferrin in some patients showed a combination
of transferrin isoforms with a lack of glycans, and abnor-
mal glycan structures lacking galactose.3 The presence of
specific clinical features, such as bifid uvula with or with-
out cleft palate at birth, in combination with abnormal pro-
tein glycosylation has alerted early suspicion of PGM1-
CDG patients, and has indeed made this a fast growing
novel CDG group. Dietary D-galactose supplementations
in 6 patients were shown to improve the glycosylation pro-
files and clinical symptoms. Especially, 2 teenage girls
exhibited a disappearance of rhabdomyolysis, and normali-
zation of hypogonadotropic hypogonadism leading to clin-
ical signs of puberty.3 Several clinical trials were
established to study the effect of oral D-galactose.4-6
In view of the broad clinical spectrum and the vari-
ety in CDG screening profiles of PGM1-CDG, the
challenge is to identify unique biochemical markers
that can unambiguously detect this disorder among the
complete spectrum of clinical presentations. In addi-
tion, the introduction of D-galactose as dietary inter-
vention necessitates the accurate monitoring of therapy
responses. To solve the diagnostic challenge of PGM1-
CDG, we performed extensive glycomics profiling of a
large group of 19 PGM1-CDG patients, covering the
full range of clinical features and including 8 patients
on oral D-galactose to find specific glycomarkers for
direct diagnosis and treatment monitoring.MATERIALS AND METHODS
All chemicals and reagents were of the highest level
of purity available. Unless otherwise stated, they were
purchased from Sigma-Aldrich.PLASMA SAMPLES
For establishment of reference ranges, plasma samples
from a control group of 20 healthy volunteers
(>18 years, n = 5; 218 years, n = 5; 1 month-2 years,
n = 5 and <1 month, n = 5) were analyzed for transferrin
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64 Abu Bakar et al September 2018isoelectric focusing (TIEF) and QTOF MS to define nor-
mal transferrin glycosylation. Plasma samples of all
patients were obtained from the diagnostics archive (Rad-
boud UMC, Nijmegen, The Netherlands) and used in
agreement with Helsinki’s Declaration. Patient samples
were from the case group of PGM1-CDG (n = 19), and a
contrast group of mild CDG-I (n = 10), galactosemia due
to GALT deficiency (n = 3), B4GALT1-CDG (n = 3),
and SLC35A2-CDG (n = 3). The group of mild CDG-I is
randomly selected from a cohort of CDG-I patient sam-
ples showing a mild increase of CDG-I transferrin glyco-
forms. The diagnosis of all PGM1-CDG patients was
genetically (Table I) and biochemically confirmed (Sup-
plementary Table I).1,3,5-8 As previously described, a
series of P12 samples covering before, during and after 6
months D-galactose therapy were analyzed to define 3
glycan-indexes from intact transferrin glycoprofiling.5
Moreover, samples from 8 PGM1-CDG patients includ-
ing P12 (Table I) before and during 3 months of D-galac-
tose therapy were available for therapy monitoring study
using the 3 defined glycan-indexes (clinicaltrials.gov
NCT02955264).5,6CDG SCREENING TESTS
Routine screening tests for protein N-glycosylation
by TIEF as well as for protein mucin type O-glycosyla-
tion by apolipoprotein C-III isoelectic focusing (IEF)
were performed as described.9HPLC-CHIP-QTOF LC-MS OF INTACT TRANSFERRIN
(TRANSFERRIN GLYCOPROFILING)
As previously described, 5 mL plasma was immuno-
precipitated with antitransferrin beads. Intact transfer-
rin MS was performed on a microfluidics-based
platform (Agilent Technologies) consisting of an Agi-
lent 1260 nanoLC-HPLC-chip system using a C8 pro-
tein chip (C8-chip) coupled to an Agilent 6540 QTOF
LC/MS system.10 Data analysis for transferrin glyco-
profiling was performed using Agilent Mass Hunter
Qualitative Analysis Software B.05. The distribution
of raw charge data was deconvoluted to reconstructed
mass data using the Agilent BioConfirm Software.10
A set of 25 transferrin glycoforms (see Table II)
was selected for relative quantitation, calculated to
their total sum of abundance. These glycoforms
were selected on the basis of their appearance in
spectra of PGM1-CDG patients and consisted of com-
plex, hybrid, and high mannose type N-glycans
(see Fig 1A). The percentage of improvement (PI)
of all glycan-indexes for treatment monitoring wascalculated based on the following formula:
index before treatmentð Þ index after treatmentð Þ
high LOGI&LOCGIð Þ or low NGIð Þ reference limit
h i
 100HPLC-CHIP-QTOF LC-MS OF TOTAL PLASMA N-
GLYCANS (TOTAL PLASMA GLYCOPROFILING)
As modified from previously described, 10 mL of
plasma was mixed in equal parts with an aqueous solution
of 200 mM ammonium bicarbonate and 10 mM dithio-
threitol.11 Protein denaturation was performed in mild
conditions by alternating between boiling temperature and
room temperature in a water bath for 6 cycles of 5 seconds
each. For enzymatic release of N-glycans, 1 mL of peptide
N-glycosidase F, PNGaseF (New England Biolabs, cata-
log no. P0704L) was added and the mixture was incubated
for 22 hours at 37˚C. To remove proteins from the gly-
cans, ethanol precipitation was performed with 80% (vol-
ume/volume; v/v) ethanol, by adding 80 mL of ethanol
and the mixture was frozen at ¡80˚C for 45 minutes. The
mixture was centrifuged at 14,000 rpm (Eppendorf) for 20
minutes and the supernatant was dried in vacuo (Thermo
RVT4104 Refrigerated Vapor Trap). Purification and
enrichment of glycans was performed using a graphitized
carbon cartridge (Grace Davison, catalog no. G4240-
64010, 150 mg, 4.0 mL). The cartridge was washed with
1.5 mL of 80% acetonitrile and 0.1% trifluoroacetic acid
(v/v) in water, and conditioned with 3.0 mL of water.
Dried samples were reconstituted with 200 mL of pure
water before applied onto the cartridge, and then washed
with 3.5 mL of pure water. Finally, plasma N-glycans
were eluted with 2.0 mL of 40% acetonitrile and 0.05%
trifluoroacetic acid (v/v) in water and dried in vacuo
(Thermo RVT4104 Refrigerated Vapor Trap).
MS was performed on a microfluidics-based platform
(Agilent Technologies) consisting of an Agilent 1260
Infinity HPLC-chip system using a porous graphitized
carbon chip (PGC-chip) and Agilent 6540 QTOF mass
spectrometer as described.12 Raw LC-MS data were ana-
lyzed using the Molecular Feature Extraction algorithm
included in Agilent Mass Hunter Qualitative Analysis
Software B.05. Using a mass tolerance of 20 ppm, decon-
voluted masses of each chromatogram peak were com-
pared against a theoretical glycan mass library (in-house)
consisting of all possible complex, hybrid, and high man-
nose type N-glycans that have been reported in human
plasma.12 Hence, only glycan compositions containing
hexose (Hex), N-acetylhexosamine (HexNAc), fucose
(Fuc), and N-acetylneuraminic acid (Neu5Ac) were
included. Relative abundances of each glycan were
obtained through normalization to the total signal of all
detected glycans. Global degalactosylation, fucosylation,
and sialylation indexes were calculated based on the total
relative abundance of degalactosylated N-glycans, fuco-
sylated N-glycans and sialylated N-glycans, respectively.
Table I. Overview of genetic and treatment data of 19 PGM1-CDG patients
Patient ID Sex/age Mutation data Galactose therapy (clinical study) Galactose therapy (for this glycan-indexes study)
(cDNA) (Protein) Treatment Patient ID References No. of samples analyzed Remarks
P1 F/22 c.988G>C p.G330R Yes P2 Tegtmeyer et al 20143 - -
c.1129G>A p.E377K P3 Wong et al 20176 2 plasma samples before and upon therapy (3 months)
P2 F/22 c.1507C>T p.R503X Yes P6 Tegtmeyer et al 20143 - -
c.1507C>T p.R503X P8 Wong et al 20176 2 plasma samples before and upon therapy (3 months)
P3 M/46 c.343A>G p.T115A Yes P1 Stojkovic et al 20091 - -
c.1145-1G>C Splice P8 Tegtmeyer et al 20143 - -
P4 F/18 c.1264C>T p.R422W Yes P1 Wong et al 20176 N/A -
c.1588C>T p.Q530X
P5 M/14 c.1010C>T p.T337M Yes P1 Ondruskova et al 20147 - -
c.1508G>A p.R503Q P2 Wong et al 20176 2 plasma samples before and upon therapy (3 months)
P6 M/18 c.361G>C G121R No P6 Wong et al 20168 N/A -
P7 M/18 c.787G>T p.D263Y No - - - -
c.788A>G p.D263G
P8 F/21 c.316T>C p.Ile106Val No - - - -
P9 F/18 c.871G>A/ p.Gly291Arg No - - - -
P10 F/6 c.689G>A p.Gly230Glu Yes P6 Wong et al 20176 2 plasma samples before and upon therapy (3 months)
P11 M/4 c.157_158delinsG p.Gln53Glyfs*15 Yes P4 Wong et al 20176 2 plasma samples before and upon therapy (3 months)
c.1507C>T p.Arg503*
c.661C>T p.Arg221Cys
c.1258T>C p.Tyr420His
P12 M/56 c.988G>C in exon 6 p.Gly330Arg Yes P1 Voermans et al 20175 6 plasma samples before, upon (1, 3, and 6 months) &
c.1258T>C in exon 8 p.Tyr420His after therapy
c.1264C>T in exon 8 p.Arg422Trp
P13 M/7 c.988G>C p.Gly330Arg Yes - - - -
c.1007C>G p.Pro336Arg
P14 F/1 c.661delinsC p.Arg221Vfs*13 Yes - - 2 plasma samples Before and upon therapy (3 months)
c.988G>C p.Gly330Arg
P15 F/3 c.419G>A p.Gly140Asp Yes - - 2 plasma samples Before and upon therapy (3 months)
c.1597C>T p.Arg533Trp
P16 M/25 c.1547T>C p.L516P No P1.2 Tegtmeyer et al 20143 - -
P17 M/17 c.1547T>C p.L516P No P1.1 Tegtmeyer et al 20143 - -
P18 M/31 c.1145-222G>T p.G382Vfs*2 No P5.1 Tegtmeyer et al 20143 - -
P19 F/25 c.1145-222G>T p.G382Vfs*2 No P5.2 Tegtmeyer et al 20143 - -
cDNA, complementary DNA; ID, Identification; F, Female; M, Male; ; N/A, not available; P, Patient.
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Table II. Transferrin glycoprofiling in PGM1-CDG and controls. Transferrin glycoforms are sorted based on their relative abundance in PGM1-CDG. Data represent the
mean and 95% CI (in %) for the reference ranges. The glycans that do not show statistically significant differences in abundance (student’s t test; P  0.05) between normal
control and PGM1-CDG are highlighted in gray
No. Assigned
structure
Glycoforms
ID (Fig 1)
Glycoform composition (with intact transferrin) Mass, Da Transferrin glycoform Reference ranges t test
Hex HexNAc dHex Neu5Ac Classification Controls (n = 20) PGM1-CDG (n = 19) (P values)
1. 25 10 8 0 4 79,557 Complete N-glycans (normal
glycoform)
92.5 (91.693.3) 43.7 (33.853.7) 1.9£ 10¡12
2. 6 5 4 0 2 77,351 Lack of 1 complete N-glycan
(CDG-I glycoforms)
2.20 (1.802.60) 15.6 (13.417.9) 1.0£ 10¡14
3. 2 3 4 0 0 76,444 Galactose lacking N-glycans
(CDG-I glycoforms)
0.06 (0.010.03) 9.76 (6.0813.4) 2.4£ 10¡6
4 1 0 0 0 0 75,144 Lack of two complete N-gly-
cans (CDG-I glycoforms)
0.08 (0.040.12) 5.48 (3.697.27) 2.1£ 10¡7
5 4 4 4 0 1 76,897 Galactose lacking N-glycans
(CDG-I glycoforms)
0.02 (0.010.03) 4.76 (3.216.31) 1.6£ 10¡7
6 24 10 8 0 3 79,265 Sialic acid only lacking N-gly-
cans (CDG-II glycoforms)
2.77 (2.243.30) 3.81 (2.664.97) 0.09
7 11 7 8 0 1 78,196 Galactose lacking N-glycans
(CDG-II glycoforms)
0.22 (0.130.31) 2.48 (1.723.24) 3.5£ 10¡7
8 8 6 8 0 0 77,743 Galactose lacking N-glycans
(CDG-II glycoforms)
0.14 (0.070.22) 2.06 (0.953.18) 9.3£ 10¡4
(continued on next page)
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Table II (Continued)
No. Assigned
structure
Glycoforms
ID (Fig 1)
Glycoform composition (with intact transferrin) Mass, Da Transferrin glycoform Reference ranges t test
Hex HexNAc dHex Neu5Ac Classification Controls (n = 20) PGM1-CDG (n = 19) (P values)
9 16 8 8 0 2 78,650 Galactose lacking N-glycans
(CDG-II glycoforms)
0.12 (0.070.16) 1.72 (1.272.18) 7.4£ 10¡9
10 3 4 4 0 0 76,606 Galactose lacking N-glycans
(CDG-I glycoforms)
0.04 (0.020.06) 1.43 (0.79  2.06) 5.0£ 10¡5
11 5 5 4 0 1 77,060 Sialic acid only lacking N-gly-
cans (CDG-I glycoforms)
0.01 (0.000.01) 1.34 (0.951.74) 1.8£ 10¡8
12 23 9 8 0 3 79,103 Galactose lacking N-glycans
(CDG-II glycoforms)
0.20 (0.130.27) 1.21 (0.871.55) 5.0£ 10¡7
13 18 9 8 0 2 78,809 Galactose lacking N-glycans
(CDG-II glycoforms)
0.10 (0.050.14) 0.95 (0.731.17) 1.2£ 10¡9
14 14 10 8 0 0 78,399 Sialic acid only lacking N-gly-
cans (CDG-II glycoforms)
0.15 (0.070.22) 0.82 (0.521.10) 3.4£ 10¡5
15 10 6 9 0 0 77,945 Galactose lacking N-glycans
(CDG-II glycoforms)
0.06 (0.010.11) 0.75 (0.291.21) 3.1£ 10¡3
(continued on next page)
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Table II (Continued)
No. Assigned
structure
Glycoforms
ID (Fig 1)
Glycoform composition (with intact transferrin) Mass, Da Transferrin glycoform Reference ranges t test
Hex HexNAc dHex Neu5Ac Classification Controls (n = 20) PGM1-CDG (n = 19) (P values)
16 12 8 6 0 2 78,240 N-acetyl glucosamine only
lacking N-glycans (CDG-II
glycoforms)
0.20 (0.100.30) 0.66 (0.400.91) 1.4£ 10¡3
17 7 6 7 0 0 77,545 Galactose lacking N-glycans
(CDG-II glycoforms)
0.20 (0.080.32) 0.64 (0.26  1.01) 2.4£ 10¡2
18 13 8 8 0 1 78,354 Galactose lacking N-glycans
(CDG-II glycoforms)
0.32 (0.240.41) 0.63 (0.440.81) 3.4£ 10¡3
19 17 10 8 0 1 78,693 Sialic acid only lacking N-gly-
cans (CDG-II glycoforms)
0.07 (0.030.10) 0.51 (0.230.78) 1.9£ 10¡3
20 19 8 9 0 2 78,853 Galactose lacking N-glycans
(CDG-II glycoforms)
0.18 (0.110.24) 0.48 (0.290.67) 3.1£ 10¡3
21 21 10 8 0 2 78,971 Sialic acid only lacking N-gly-
cans (CDG-II glycoforms)
0.12 (0.060.18) 0.40 (0.240.56) 1.3£ 10¡3
22 15 10 6 0 2 78,560 High mannose glycans (CDG-II
glycoforms)
0.05 (0.010.08) 0.32 (0.150.49) 2.4£ 10¡3
(continued on next page)
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Table II (Continued)
No. Assigned
structure
Glycoforms
ID (Fig 1)
Glycoform composition (with intact transferrin) Mass, Da Transferrin glycoform Reference ranges t test
Hex HexNAc dHex Neu5Ac Classification Controls (n = 20) PGM1-CDG (n = 19) (P values)
23 9 7 8 0 0 77,900 galactose lacking N-glycans
(CDG-II glycoforms)
0.05 (0.02  0.08) 0.24 (0.010.50) 0.13
24 22 10 7 0 3 79,064 Hybrid glycans (CDG-II
glycoforms)
0.21 (0.090.32) 0.13 (0.070.18) 0.19
25 20 9 7 0 3 78,900 N-acetyl glucosamine only
lacking N-glycans (CDG-II
glycoforms)
0.05 (0.000.11) 0.10 (0.040.15) 0.24
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Data were analyzed using GraphPad Prism (version
5.03) and IBM SPSS (version 22.0) software. Using a
parametric approach, central 95% confidence intervals
in the control group (n = 20) were used to express the
reference limits. For the 3 selected transferrin glyco-
forms (glycoform 2, 4, and 6) and their prediction
model, and also for the 6 global glycosylation indexes,
student’s t test was used for the specific comparison of
glycans’ relative abundance between PGM1-CDG and
other groups (control and contrast groups). P values of
0.05 were considered significant. Backward (condi-
tional) logistic regression of the glycoforms 2, 4, and 6
was performed using the SPSS to determine the equa-
tion variables (slope and y-intercept), for the calcula-
tion of the prediction model (linear regression)
between PGM1-CDG and other groups (control and
contrast groups). Receiver Operating Characteristic
curve analysis was performed using the GraphPad
Prism to calculate the diagnostic value (sensitivity and
specificity), and the Area Under Curve (AUC) of the 3
combined transferrin glycoforms (P < 0.0001) forFig 1. Heterogeneity of transferrin profiles in PGM1-CDG.
P11 showed a clear mixed CDG-I/CDG-II pattern of TIEF
QTOF showed a high intensity of the peak indicating lack o
of galactose lacking N-glycans (eg, glycoform 2, 4, 11, 16, 1
P3 showed a mild CDG-II transferrin IEF. Deconvoluted m
lack of 1 complete glycan (glycoform 6) as the highest abno
degalactosylated glycoforms as also seen in severe PGM1-
normal control profile and corresponding IEF showed a no
most abundant transferrin glycoform in healthy subjects.discriminating between PGM1-CDG and other groups
(control and contrast groups).RESULTS
PGM1-CDG in routine CDG screening. PGM1-CDG can present as a
mixed CDG-I and CDG-II screening profile by TIEF, but has also been
identified in CDG-I cohorts.2 In our study of 19 patients (Fig 1 and Sup-
plementary Table I), a mixed profile with elevated asialo- and disialo-
transferrin (CDG-I) was observed, in addition to elevated monosialo- and
trisialotransferrin (CDG-II). Simultaneously, CDG screening in our
PGM1-CDG cohort revealed patients with a more predominant CDG-I
profile (Fig 1A) and others with mild CDG-II screening profile (Fig 1B),
indistinguishable from other CDG-II defects. In view of the galactose
lacking glycans in PGM1-CDG patients, we also performed CDG screen-
ing for mucin type O-glycosylation by Apo-CIII IEF in 9 patients (Sup-
plementary Table I). No defect in mucin type O-glycosylation was
observed, showing that PGM1-CDG most probably only affects protein
N-glycosylation.
Glycomics profiling for the diagnosis of PGM1-CDG. To gain more
insight into the exact structural changes, high-resolution QTOF MS
of intact plasma transferrin was performed. Our study of 19 PGM1-
CDG patients showed a broad range of MS spectra from severe
PGM1-CDG profiles (eg, patient 11, P11) (Fig. 1, A) to mild PGM1-
CDG profiles (eg, patient 3, P3) (Fig 1, B). The controls (Fig 1, C)(A) Severe or typical PGM1-CDG profiles as seen in
. Deconvoluted mass spectrum of intact transferrin
f complete glycans (glycoform 1 and 6) and a series
8, and 23). (B) Mild PGM1-CDG profiles as seen in
ass spectrum of intact transferrin QTOF revealed a
rmal peak as well as a series of typical PGM1-CDG
CDG profiles. (C) Deconvoluted mass spectrum of
rmal transferrin glycoforms (glycoform 25) as the
Fig 2. PGM1-CDG specific glycomarkers derived from glycoprofiling of intact transferrin. (A) Relative abun-
dance of glycoform 6 (77,351 Da), the most abundant abnormal transferrin glycoform in PGM1-CDG. This
CDG-I glycoform lacking 1 complete glycan, serves as a good marker to distinguish PGM1-CDG from CDG-II;
(B) Relative abundance of glycoform 2 (76,444 Da) which is the most abundant degalactosylated glycoform in
PGM1-CDG. This glycoform can also be seen in other galactose related CDG-II defects, such as B4GALT1-
CDG and SLC35A2-CDG; (C) Relative abundance of glycoform 4 (76,897 Da), the only glycoform that allows
discrimination of PGM1-CDG from other CDG group. However, this glycoform can’t serve as a single glyco-
marker for PGM1-CDG because of its low abundance in some mild PGM1-CDG profiles; (D) The combination
of 3 transferrin glycoforms (glycoform 6, 77,351 Da, glycoform 2, 76,444 Da, and glycoform 4, 76,897 Da) in a
linear regression model showed a 100% discrimination of PGM1-CDG (n = 19) from normal controls (n = 20),
mild CDG-I (n = 10), B4GALT1-CDG (n = 3), SLC35A2-CDG (n = 3) and galactosemia (n = 3).
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with 2 complete biantennary N-glycans (glycoform 25, 79,557 Da).
In severe PGM1-CDG cases (Fig 1, A), dominant transferrin glyco-
forms of typical CDG-I were observed with a lack of 1 and 2 com-
plete glycans (glycoform 6, 77,351 Da, and glycoform 1, 75,144 Da,
respectively) and of mixed CDG-I and CDG-II with a lack of 1 com-
plete glycan and galactose (glycoforms 2, 76,444 Da, and 4, 76,897
Da). Other CDG-II glycoforms were of lower abundance (glycoforms
3, 5, and 7-24). In mild PGM1-CDG profiles (Fig 1, B), the most
abundant abnormal peak reflected a CDG-I glycoform lacking 1complete glycan (glycoform 6; 77,351 Da) with only minor peaks
corresponding to degalactosylated glycoforms. In contrast, TIEF pro-
files of this patient showed a mild CDG-II pattern (Fig 1, B), which
complicates the diagnosis. However, both severe and mild PGM1-
CDG MS profiles exhibited the same glycomics signature, namely
the lack of complete glycans and galactose residues.
We then selected a comprehensive set of 25 transferrin glyco-
forms (Table II) for relative quantification and for discovery of spe-
cific glycomarkers for the unambiguous diagnosis of both mild and
severely affected PGM1-CDG patients. We compared the relative
Fig 3. Total plasma glycoprofiling of the 6 glycan groups in PGM1-CDG. The relative abundance of 3 major
classes of N-glycans, namely complex type N-glycans (A), hybrid type N-glycans, (B), and high mannose type
N-glycans (C), in controls and PGM1-CDG patients. Global glycosylation indexes of degalactosylation (D),
fucosylation (E), and sialylation (F), of the same subjects were also shown. In the majority of patients, complex
glycans, hybrid glycans and sialylation index were reduced while high mannose glycans, degalactosylation index
and fucosylation were increased as compared with controls. Data represent the mean and 95% CI (in %) for the
reference ranges.
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Table III. Total plasma N-glycans during D-galactose therapy.The 6 main glycan groups (Fig 3) before and after D-galac-
tose treatment for P12. Data represent the mean and 95% CI (in %) for the reference ranges
Relative abundance, % Reference ranges
Glycan types / indexes P12 Before treatment (month = 0) After treatment (month = 6) (n = 20)
Complex type glycans 88.8 91.7 91.7 (91.192.3)
Hybrid type glycans 2.0 3.0 3.5 (3.23.8)
High mannose type glycans 9.3 5.3 4.8 (4.35.2)
Degalactosylation index 58.8 34.7 27.9 (26.229.6)
Fucosylation index 46.7 43.6 41.9 (40.243.6)
Sialylation index 36.0 65.7 71.0 (69.672.4)
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tially overlapping disease groups based on their glycomics profiling,
including mild CDG-I and galactosemia (potentially mimicking mild
PGM1-CDG) and 2 classes of CDG-II that are known to display
galactose lacking glycans profile (B4GALT1-CDG and SLC35A2-
CDG). The 2 most striking abnormal transferrin glycoforms in
PGM1-CDG are glycoform 6 (77,351 Da) and glycoform 2 (76,444
Da). Glycoform 6 alone is a useful marker to differentiate PGM1-
CDG from other CDG-II defects (eg, B4GALT1-CDG, etc), but is
present at similar moderately elevated levels in mild CDG-I and
galactosemia patients (Fig 2, A). Glycoform 2 is highly characteristic
for PGM1-CDG, however, this glycoform was also present in other
types of galactosylation defects such as B4GALT1-CDG and
SLC35A2-CDG (Fig 2, B). Further analysis on the relative abun-
dance of other glycoforms in all 5 disease-groups revealed that glyco-
form 4 (76,897 Da) was the only single transferrin isoform that was
specific for PGM1-CDG. Due to its low abundance, this isoform can-
not serve as a single marker for PGM1-CDG in some of the PGM1-
CDG patients (Fig 2, C). We then combined all of these 3 transferrin
glycoforms (glycoform 6, 77,351 Da; glycoform 2, 76,444 Da; and
glycoform 4, 76,897 Da) and performed regression analysis to estab-
lish a prediction model for PGM1-CDG diagnosis. Finally, we
showed that these 3 transferrin glycoforms are specific to PGM1-
CDG (Fig 2, D) with 100% sensitivity and specificity in discriminat-
ing PGM1-CDG from normal controls (AUC = 1.0, P < 0.0001),
mild CDG-I (AUC = 1.0, P < 0.0001), B4GALT1-CDG, SLC35A2-
CDG, and galactosemia.
To investigate whether global N-glycosylation profiles can add
value in PGM1-CDG diagnosis, we performed total plasma N-glycan
profiling on all patients and 20 normal controls (Fig 3, and Supple-
mentary Table 2). In addition, we also compared this glycomics pro-
filing with B4GALT1-CDG and SLC35A2-CDG, which are known
to show the high degree of global degalactosylation.13,14 For the 3
major classes of N-glycans, the total relative abundance of complex
type N-glycans (Fig 3, A) and hybrid type N-glycans (Fig 3, B) were
reduced, while an increase was seen of high mannose type N-glycans
(Fig 3, C) for the majority of patients. Further analysis on 3 global
glycosylation indexes showed a very high degalactosylation index
(Fig 3, D), which is in agreement with intact transferrin N-glycan
profiles, an overall increase in the degree of fucosylation (Fig 3, E),
and a reduction in sialylated N-glycans (Fig 3, F). As depicted from
Figure 3, AF, global galactosylation and sialylation were severely
reduced in PGM1-CDG, B4GALT1-CDG, and SLC35A2-CDG,
while global high mannose glycans and fucosylation were increased
only in PGM1-CDG and SLC35A2-CDG.
Therapy monitoring in PGM1-CDG. Next, we aimed to explore the
potential of glycoprofiling for monitoring the effectiveness of D-
galactose supplementation in PGM1-CDG. After 6 months on oral
D-galactose therapy, total plasma glycoprofiling in P12 showed an
improvement of glycosylation in all 6 main glycan-indexes(Table III), indicating normalization of plasma protein N-glycosyla-
tion due to D-galactose supplementation. Improved addition of D-
galactose to protein glycans after 6 months of D-galactose supple-
mentation was seen from an increase of complex type N-glycans
(from 88.8% to 91.7%), hybrid type-N-glycans (from 2.0% to 3.0%)
and total sialylated N-glycans; sialylation index (from 36.0 to 65.7),
and a decrease of high mannose type-N-glycans (from 9.3% to 5.3%)
and total degalactosylated N-glycans; degalactosylation index (from
58.8 to 34.7). In addition, total plasma glycoprofiling showed an
effect of D-galactose supplementation on the fucosylation level, with
a decrease of total fucosylated N-glycans (from 46.7 to 43.6) to near
normal. A similar improvement in global galactosylation, sialylation
and fucosylation was observed in P1, P5, P14, and P15 after 3 months
of D-galactose treatment, while fucosylation is maintained at a high
level in P10 and increased in P2 and P11 (Supplementary Table III).
Only P15 showed normalization of global galactosylation, sialyla-
tion, and fucosylation indexes.
Total plasma glycoprofiling is influenced by relative protein abun-
dance and does not allow the detection of a lack of complete glycans
(glycan loss), which is one of the main glycomics signatures for
PGM1-CDG. Therefore, we defined 3 glycan-indexes from the trans-
ferrin QTOF spectra that are useful in clinical practice to monitor the
therapeutic efficiency of dietary D-galactose in PGM1-CDG. As
index to monitor the overall level of normalization, a Normal Glycan
Index (NGI) was previously defined as the relative abundance of fully
glycosylated transferrin (glycoform 25; 79,557 Da).5 To discriminate
the 2 main effects of PGM1 deficiency on glycosylation, we defined
a Lack of Complete Glycan Index (LOCGI) and a Lack of Galactose
Index (LOGI). For LOCGI, we used the relative abundance of glyco-
forms 1 and 6, lacking both and 1 glycan, respectively. For LOGI, we
used the relative abundance of 6 degalactosylated glycoforms (glyco-
forms 2, 4, 11, 16, 18, and 23; See Table II and Supplementary Fig
1).
We used these glycan-indexes to study the effect of D-galactose
therapy in 8 patients treated for 3 months. All patients showed an
improvement of the transferrin glycoprofiles. For P12, the NGI
showed near-normalization, indicating a good response to D-galac-
tose treatment (Fig 4, A). The LOGI showed a fast response during
D-galactose therapy (Fig 4, B), while the lack of complete glycans
was restored more slowly, as displayed in the LOCGI (Fig 4, C). The
percentage of improvement (PI) for 3 transferrin glycosylation
indexes showed 82% normalization for NGI, 97% normalization for
galactosylation (LOGI) and 73% normalization for the lack of com-
plete glycans (LOCGI) after 6 months of D-galactose therapy. After
discontinuation of D-galactose supplementation, the NGI, LOGI, and
LOCGI worsened (Fig 4, A-C). The clinical and other biochemical
improvements of P12 after 6 months galactose therapy have been
reported in the previous study.5 The TIEF and transferrin QTOF pro-
files of P12 before and upon galactose therapy are shown in Supple-
mentary Figure 1.
Fig 4. Transferrin glycoprofiling for therapy monitoring. The 3 glycan-indexes, (A) Normal Glycosylation
Index (NGI), (B) Lack of Galactose Index (LOGI), and (C) Lack Of Complete Glycans Index (LOCGI), defined
for therapy monitoring in PGM1-CDG were used to monitor the response of P12 before, upon and after 6 months
D-galactose supplementation. The same transferrin indexes for (D) normal glycosylation (NGI), (E) galactose
lacking glycans (LOGI), and (F) lack of complete glycans (LOCGI) are also shown on P1, P2, P5, P10, P11,
P12, P14, and P15 to monitor the transferrin glycosylation improvements after 3 months of D-galactose therapy.
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galactose index; LOGI (Fig 4, E) and slower recovery of the lack of
complete glycans; LOCGI (Fig 4, F) was also observed in the majority
of patients (P1, P2, P5, P12, P14, and P15) after 3 months of D-galactose
therapy. Slow improvement of NGI, LOGI, and LOCGI was observed in
P10 and P11, in whom the LOCGI restoration is more pronounced than
LOGI.DISCUSSION
The high clinical and biochemical heterogeneity in
PGM1-CDG complicates diagnosis and necessitatesthe search for a specific marker for fast and accurate
detection and evaluation of follow-up and treatment. In
this study, we have solved the diagnostic challenge of
PGM1-CDG by high resolution MS analysis of plasma
transferrin. We here present a specific and reliable
diagnostic test, which allows an automated way to
diagnose PGM1 in large cohorts. The combination of 3
transferrin glycoforms was diagnostic for PGM1-CDG
with high sensitivity and specificity. In addition, we
defined 3 glycan-indexes to specifically monitor the
normalization or improvement of transferrin glyco-
forms upon D-galactose supplementation.
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both degalactosylated and fucosylated glycans. An
increase of global fucosylation in the majority of
PGM1-CDG patients has not been reported before.
Since transferrin is a known protein with a low degree
of fucosylation, this is an added value of total plasma
glycomics. This novel finding also adds the PGM1-
CDG to the subset of CDGs with high fucosylation pro-
files. Hyperfucosylation is associated with chronic
hepatic inflammation, which can also be seen in
PMM2-CDG (CDG-I) and B4GALT1-CDG.13,15,16
However, neither fucosylation nor degalactosylation is
specific for PGM1-CDG. Furthermore, the lack of
complete glycans cannot be detected by total plasma
glycoprofiling, which is the most important marker for
sensitive detection of PGM1-CDG. Remarkably, an
increase of global high mannose N-glycans in PGM1-
CDG was also observed, similar to all patients with a
UDP-galactose transporter defect (SLC35A2-CDG).
Several cellular glycomics studies have shown an
increase of high mannose glycans, particularly regard-
ing Immnoglobulin G (IgG) glycosylation, attributed
to: (1) a change in cellular nucleotide-sugar content
(eg, UDP-galactose), which occurs in PGM1-CDG and
SLC35A2-CDG;17 (2) an increased osmolality and pH
of Golgi and/or ER, which is common in CDG such as
TMEM199-CDG;9,18 (3) a low glucose concentration
which is reflected by the hypoglycemia in PGM1-
CDG;19 and (4) an increased concentration of intracel-
lular mannose and/or overactive GDP-mannose syn-
thetic pathway which produce proteins with elevated
levels of high mannose glycans.20
The high sensitivity and specificity of the combina-
tion of 3 transferrin glycoforms for PGM1-CDG under-
line the advantage of protein specific glycoprofiling for
direct diagnosis of PGM1-CDG. The improvement over
total plasma N-glycan analysis relates to: (1) the ioniza-
tion of the glycoforms were dominated by the amino
acid backbone, which improved relative quantification
of glycans; (2) variations in protein concentrations were
eliminated, which resulted in smaller reference ranges
from healthy individuals. Also large population based
serum glycomics studies show the interindividual gly-
come heterogeneity, which likely reflects the genetic,
epigenetic, and metabolic systems.21 The approach of
intact protein glycoprofiling is attractive because of its
robustness and fast analysis. This was also shown by a
recent study that revealed the potential of intact hapto-
globin glycoprofiling as a promising marker for cancer
screening.22 From a diagnostic point of view, the dis-
covery of these glycomarkers has positioned transferrin
QTOF MS as the primary test for PGM1-CDG with a
turnaround time of only 2 hours.Our previous study showed the biochemical
improvement of D-galactose supplementation by trans-
ferrin glycoprofiling.3,5,6 A specific and reliable diag-
nostic test is highly relevant since patients can present
in a variety of clinical cohorts such as liver disease,
exercise intolerance, or cardiomyopathy. Furthermore,
early diagnosis and treatment might save the damage
to muscles, liver, and heart. We introduced NGI,
LOCGI, and LOGI from transferrin glycoprofiling to
monitor D-galactose treatment and progression in
PGM1-CDG. These indexes are more specific than the
previous study especially to monitor the improvement
of lack of galactose residues (LOGI) after galactose
supplementation.5,6 We showed for 6 patients that D-
galactose therapy drastically improved the normaliza-
tion of LOGI, which might easily be explained by the
conversion of galactose to galactose-1-phosphate and
subsequently to uridine diphosphate galactose, UDP-
galactose. This can be rapidly used as a building block
for protein glycosylation. Two patients showed a more
pronounced improvement of the LOCGI than of the
LOGI after 3 months of D-galactose therapy. It remains
an open question how the D-galactose supplementation
can improve the addition of glycans to proteins in the
ER as shown by the improvement of the LOCGI. One
next step is to relate the biochemical normalization of
transferrin glycan-indexes (NGI, LOCGI, and LOGI)
to the improvement of clinical features. This also offers
an opportunity for clinicians to further optimize D-
galactose supplementation (dosage, period, and alter-
native pharmacologic formulae) in order to achieve
maximal biochemical and clinical effect.
In conclusion, transferrin glycoprofiling revealed a
highly sensitive and specific glycomarker for the diag-
nosis of PGM1-CDG in its full clinical spectrum. In
addition, 3 glycan-indexes are proposed, NGI, LOGI,
and LOCGI, to monitor the effectiveness of D-galac-
tose therapy in PGM1-CDG. This allows discriminat-
ing the response of endoplasmic reticulum versus
Golgi glycosylation defect. We expect that these glyco-
markers result in the diagnosis of additional PGM1-
CDG patients and in guiding the further optimization
of oral D-galactose as supplementation therapy.ACKNOWLEDGMENTS
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